US equities
|
MU
$1,086.74
▲+3.94%
NVDA
$236.76
▼-1.04%
SNDK
$1,720.79
▲+3.63%
SPCX
$166.97
▼-2.88%
AMD
$644.70
▼-0.73%
TSLA
$377.47
▼-0.84%
INTC
$112.69
▲+0.17%
AAPL
$336.53
▲+0.87%
MU
$1,086.74
▲+3.94%
NVDA
$236.76
▼-1.04%
SNDK
$1,720.79
▲+3.63%
SPCX
$166.97
▼-2.88%
AMD
$644.70
▼-0.73%
TSLA
$377.47
▼-0.84%
INTC
$112.69
▲+0.17%
AAPL
$336.53
▲+0.87%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Palvella Therapeutics, Inc. - Common Stock
(NQ:
PVLA
)
130.82
+2.82 (+2.20%)
Delayed Quote
Updated: 2:51 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Palvella Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
April 02, 2025
Presentation to highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
March 31, 2025
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
March 18, 2025
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Earnings Scheduled For March 31, 2025
↗
March 31, 2025
Via
Benzinga
Pavella - Undiscovered Biotechnology Stock
↗
March 12, 2025
The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials.
Via
Talk Markets
Topics
Stocks / Equities
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
February 25, 2025
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
February 20, 2025
Via
Benzinga
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
February 10, 2025
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
↗
February 05, 2025
Via
Benzinga
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
January 10, 2025
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
January 08, 2025
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
